{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T11:51:42Z","timestamp":1792929102926,"version":"4.5.0"},"reference-count":57,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,8,14]]},"abstract":"<jats:title>Key Points<\/jats:title><jats:p>Intermediate-dose cytarabine can be safely combined with TDZ at 50 mg every 6 hours in older patients with relapsed or refractory AML. A 5-day monotherapy with TDZ led to reduced blast counts in 5 out of 11 patients and was associated with patient-specific DRD2 level.<\/jats:p>","DOI":"10.1182\/bloodadvances.2018015677","type":"journal-article","created":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T20:18:50Z","timestamp":1536956330000},"page":"1935-1945","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":42,"title":["A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia"],"prefix":"10.1182","volume":"2","author":[{"given":"Lili","family":"Aslostovar","sequence":"first","affiliation":[{"name":"Stem Cell and Cancer Research Institute and"},{"name":"Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison L.","family":"Boyd","sequence":"additional","affiliation":[{"name":"Stem Cell and Cancer Research Institute and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Almakadi","sequence":"additional","affiliation":[{"name":"Stem Cell and Cancer Research Institute and"},{"name":"Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada;"},{"name":"Division of Malignant Hematology, Department of Oncology, Juravinski Hospital, Hamilton, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony J.","family":"Collins","sequence":"additional","affiliation":[{"name":"Stem Cell and Cancer Research Institute and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darryl P.","family":"Leong","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Population Health Research Institute, McMaster University, Hamilton, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rommel G.","family":"Tirona","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Western Ontario, London Health Sciences Centre, London, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Western Ontario, London Health Sciences Centre, London, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim A.","family":"Julian","sequence":"additional","affiliation":[{"name":"Department of Oncology, McMaster University, Juravinski Hospital, Hamilton, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anargyros","family":"Xenocostas","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, University of Western Ontario, London Health Sciences Centre, London, ON, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Leber","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University, Juravinski Hospital, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark N.","family":"Levine","sequence":"additional","affiliation":[{"name":"Department of Oncology, McMaster University, Juravinski Hospital, Hamilton, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan","family":"Foley","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Medicine, McMaster University, Juravinski Hospital, Hamilton, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9304-5130","authenticated-orcid":false,"given":"Mickie","family":"Bhatia","sequence":"additional","affiliation":[{"name":"Stem Cell and Cancer Research Institute and"},{"name":"Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2018,8,9]]},"reference":[{"issue":"3","key":"2019111619372796800_B1","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1182\/blood.V98.3.548","article-title":"Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine","volume":"98","author":"Stone","year":"2001","journal-title":"Blood"},{"issue":"3","key":"2019111619372796800_B2","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"D\u00f6hner","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2019111619372796800_B3","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"7","key":"2019111619372796800_B4","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/ajh.23464","article-title":"5-Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy","volume":"88","author":"Ivanoff","year":"2013","journal-title":"Am J Hematol"},{"issue":"9","key":"2019111619372796800_B5","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.3109\/10428194.2012.762093","article-title":"Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia","volume":"54","author":"Ritchie","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2019111619372796800_B6","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.cell.2012.03.049","article-title":"Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells","volume":"149","author":"Sachlos","year":"2012","journal-title":"Cell"},{"issue":"21","key":"2019111619372796800_B7","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1001\/jama.1983.03330450061027","article-title":"Thioridazine-induced torsade de pointes. Successful therapy with isoproterenol","volume":"249","author":"Kemper","year":"1983","journal-title":"JAMA"},{"issue":"1","key":"2019111619372796800_B8","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/01.jcp.0000104913.75206.62","article-title":"A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition","volume":"24","author":"Harrigan","year":"2004","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"2019111619372796800_B9","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1046\/j.1440-1614.2002.01045.x","article-title":"Cardiotoxicity and prescription of thioridazine in New Zealand","volume":"36","author":"Menkes","year":"2002","journal-title":"Aust N Z J Psychiatry"},{"issue":"9209","key":"2019111619372796800_B10","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S0140-6736(00)02035-3","article-title":"QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients","volume":"355","author":"Reilly","year":"2000","journal-title":"Lancet"},{"issue":"20","key":"2019111619372796800_B11","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2011.37.9743","article-title":"Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial","volume":"30","author":"Faderl","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111619372796800_B12","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2307\/2531693","article-title":"Design and analysis of phase I clinical trials","volume":"45","author":"Storer","year":"1989","journal-title":"Biometrics"},{"issue":"3","key":"2019111619372796800_B13","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1124\/dmd.105.006445","article-title":"Characterization of human cytochrome p450 enzymes involved in the metabolism of the piperidine-type phenothiazine neuroleptic thioridazine","volume":"34","author":"W\u00f3jcikowski","year":"2006","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"2019111619372796800_B14","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/sj.clpt.6100406","article-title":"The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype","volume":"83","author":"Gaedigk","year":"2008","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"2019111619372796800_B15","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nrcardio.2015.65","article-title":"Cardiotoxicity of anticancer treatments","volume":"12","author":"Ewer","year":"2015","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"2019111619372796800_B16","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3109\/15563659509017984","article-title":"Cardiotoxicity more common in thioridazine overdose than with other neuroleptics","volume":"33","author":"Buckley","year":"1995","journal-title":"J Toxicol Clin Toxicol"},{"issue":"3","key":"2019111619372796800_B17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00002018-200023030-00004","article-title":"Cardiovascular adverse effects of antipsychotic drugs","volume":"23","author":"Buckley","year":"2000","journal-title":"Drug Saf"},{"issue":"4","key":"2019111619372796800_B18","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1177\/026988110201600411","article-title":"QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients","volume":"16","author":"LLerena","year":"2002","journal-title":"J Psychopharmacol"},{"issue":"5","key":"2019111619372796800_B19","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0009-9236(96)90150-2","article-title":"Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans","volume":"60","author":"Hartigan-Go","year":"1996","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"2019111619372796800_B20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0378-4274(84)90215-7","article-title":"Thioridazine-5-sulfoxide cardiotoxicity in the isolated, perfused rat heart","volume":"21","author":"Hale","year":"1984","journal-title":"Toxicol Lett"},{"issue":"1","key":"2019111619372796800_B21","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/0041-008X(86)90398-4","article-title":"Cardiotoxicity of thioridazine and two stereoisomeric forms of thioridazine 5-sulfoxide in the isolated perfused rat heart","volume":"86","author":"Hale","year":"1986","journal-title":"Toxicol Appl Pharmacol"},{"issue":"2","key":"2019111619372796800_B22","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/jps.2600670208","article-title":"Plasma concentrations of thioridazine metabolites and ECG abnormalities","volume":"67","author":"Gottschalk","year":"1978","journal-title":"J Pharm Sci"},{"issue":"2","key":"2019111619372796800_B23","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-2125.1977.tb00691.x","article-title":"Measurement of thioridazine in blood and urine","volume":"4","author":"Ng","year":"1977","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"2019111619372796800_B24","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0022-3565(25)21626-3","article-title":"Effects of thioridazine and its metabolites on dopaminergic function: drug metabolism as a determinant of the antidopaminergic actions of thioridazine","volume":"231","author":"Kilts","year":"1984","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"2019111619372796800_B25","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0022-3565(25)32494-8","article-title":"Interactions of neuroleptic metabolites with dopaminergic, alpha adrenergic and muscarinic cholinergic receptors","volume":"217","author":"Bylund","year":"1981","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"2019111619372796800_B26","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/sj.bjp.0703540","article-title":"Pharmacokinetics and metabolism of thioridazine during co-administration of tricyclic antidepressants","volume":"131","author":"Daniel","year":"2000","journal-title":"Br J Pharmacol"},{"issue":"2","key":"2019111619372796800_B27","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/BF00562905","article-title":"Plasma levels and half lives of thioridazine and some of its metabolites. I. High doses in young acute schizophrenics","volume":"11","author":"Vanderheeren","year":"1977","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"2019111619372796800_B28","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00228-003-0576-4","article-title":"Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype","volume":"59","author":"Berecz","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"2019111619372796800_B29","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s002280050128","article-title":"Replacement of (R)-methadone by a double dose of (R,S)-methadone in addicts: interindividual variability of the (R)\/(S) ratios and evidence of adaptive changes in methadone pharmacokinetics","volume":"50","author":"Eap","year":"1996","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"2019111619372796800_B30","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2217\/pgs.09.57","article-title":"Relevance of CYP2D6 -1584C>G polymorphism for thioridazine:mesoridazine plasma concentration ratio in psychiatric patients","volume":"10","author":"Dorado","year":"2009","journal-title":"Pharmacogenomics"},{"issue":"2","key":"2019111619372796800_B31","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.0306-5251.2001.01548.x","article-title":"Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs","volume":"53","author":"Bertilsson","year":"2002","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"2019111619372796800_B32","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/00007691-199612000-00001","article-title":"Influence of Cyp2D6 genetic polymorphism on ratios of steady-state serum concentration to dose of the neuroleptic zuclopenthixol","volume":"18","author":"Linnet","year":"1996","journal-title":"Ther Drug Monit"},{"issue":"1","key":"2019111619372796800_B33","first-page":"42","article-title":"6. Dose adjustments based on pharmacogenetics of CYP450 enzymes","volume":"19","author":"van Schaik","year":"2008","journal-title":"EJIFCC"},{"issue":"10","key":"2019111619372796800_B34","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1182\/blood-2003-11-3775","article-title":"Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia","volume":"103","author":"Smith","year":"2004","journal-title":"Blood"},{"issue":"12","key":"2019111619372796800_B35","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1002\/cncr.21589","article-title":"Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia","volume":"104","author":"Bug","year":"2005","journal-title":"Cancer"},{"issue":"3","key":"2019111619372796800_B36","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1158\/1078-0432.CCR-16-0984","article-title":"A phase 1 study of the PARP inhibitor veliparib in combination with temozolomide in acute myeloid leukemia","volume":"23","author":"Gojo","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"4194","key":"2019111619372796800_B37","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1126\/science.1145194","article-title":"Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons","volume":"188","author":"Seeman","year":"1975","journal-title":"Science"},{"issue":"6","key":"2019111619372796800_B38","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"issue":"7","key":"2019111619372796800_B39","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nm0797-730","article-title":"Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell","volume":"3","author":"Bonnet","year":"1997","journal-title":"Nat Med"},{"issue":"11","key":"2019111619372796800_B40","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1056\/NEJMoa0912228","article-title":"Persistent malignant stem cells in del(5q) myelodysplasia in remission","volume":"363","author":"Tehranchi","year":"2010","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111619372796800_B41","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1182\/blood.V68.6.1185.1185","article-title":"Clonogenic cells in acute myeloblastic leukemia","volume":"68","author":"Griffin","year":"1986","journal-title":"Blood"},{"issue":"3","key":"2019111619372796800_B42","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ajh.2830150304","article-title":"The clonogenic assay as a reproducible in vitro system to study predictive parameters of treatment outcome in acute nonlymphoblastic leukemia","volume":"15","author":"Browman","year":"1983","journal-title":"Am J Hematol"},{"issue":"3","key":"2019111619372796800_B43","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1182\/blood.V56.3.361.bloodjournal563361","article-title":"Prediction of response to chemotherapy in acute myelocytic leukemia","volume":"56","author":"Preisler","year":"1980","journal-title":"Blood"},{"issue":"6","key":"2019111619372796800_B44","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.ccr.2012.11.002","article-title":"Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL","volume":"22","author":"Nagel","year":"2012","journal-title":"Cancer Cell"},{"issue":"6","key":"2019111619372796800_B45","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.ccell.2016.05.002","article-title":"Inhibition of dopamine receptor D4 impedes autophagic flux, proliferation, and survival of glioblastoma stem cells","volume":"29","author":"Dolma","year":"2016","journal-title":"Cancer Cell"},{"issue":"9","key":"2019111619372796800_B46","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/nn.4088","article-title":"EAG2 potassium channel with evolutionarily conserved function as a brain tumor target","volume":"18","author":"Huang","year":"2015","journal-title":"Nat Neurosci"},{"issue":"5","key":"2019111619372796800_B47","doi-asserted-by":"crossref","first-page":"e1753","DOI":"10.1038\/cddis.2015.77","article-title":"Identification of thioridazine, an antipsychotic drug, as an antiglioblastoma and anticancer stem cell agent using public gene expression data","volume":"6","author":"Cheng","year":"2015","journal-title":"Cell Death Dis"},{"issue":"3","key":"2019111619372796800_B48","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.biomaterials.2013.10.049","article-title":"Co-delivery of thioridazine and doxorubicin using polymeric micelles for targeting both cancer cells and cancer stem cells","volume":"35","author":"Ke","year":"2014","journal-title":"Biomaterials"},{"issue":"1","key":"2019111619372796800_B49","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ygyno.2010.10.003","article-title":"A gene signature-based approach identifies thioridazine as an inhibitor of phosphatidylinositol-3\u2032-kinase (PI3K)\/AKT pathway in ovarian cancer cells","volume":"120","author":"Rho","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"3","key":"2019111619372796800_B50","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.mvr.2012.09.006","article-title":"Anti-angiogenic effects of thioridazine involving the FAK-mTOR pathway","volume":"84","author":"Byun","year":"2012","journal-title":"Microvasc Res"},{"issue":"1","key":"2019111619372796800_B51","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJM199601043340109","article-title":"Schizophrenia","volume":"334","author":"Kane","year":"1996","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111619372796800_B52","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/jac\/dkr500","article-title":"Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin and thioridazine","volume":"67","author":"Abbate","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2019111619372796800_B53","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3389\/fphar.2014.00174","article-title":"Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research","volume":"5","author":"Tuntland","year":"2014","journal-title":"Front Pharmacol"},{"issue":"5","key":"2019111619372796800_B54","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/j.1600-0447.1992.tb10325.x","article-title":"Neuroleptic medication and reduced risk of prostate cancer in schizophrenic patients","volume":"85","author":"Mortensen","year":"1992","journal-title":"Acta Psychiatr Scand"},{"issue":"2-3","key":"2019111619372796800_B55","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.schres.2004.11.009","article-title":"Risk for cancer in a cohort of patients hospitalized for schizophrenia in Denmark, 1969-1993","volume":"75","author":"Dalton","year":"2005","journal-title":"Schizophr Res"},{"issue":"1","key":"2019111619372796800_B56","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/blood-2004-03-0891","article-title":"Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412","volume":"105","author":"Stone","year":"2005","journal-title":"Blood"},{"issue":"5","key":"2019111619372796800_B57","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/15\/1935\/881270\/advances015677.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/15\/1935\/881270\/advances015677.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T10:22:44Z","timestamp":1751883764000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/2\/15\/1935\/15949\/A-phase-1-trial-evaluating-thioridazine-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,9]]},"references-count":57,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2018,8,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2018015677","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,9]]}}}